Understanding pancreatic cancer genomes

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 20, Issue 6, 2013, Pages 549-556

  Cowley, Mark J ^a,b   Chang, David K ^a,b,c,d,e,f   Pajic, Marina ^a,b   Johns, Amber L ^a,b   Waddell, Nicola ^g   Grimmond, Sean M ^g   Biankin, Andrew V ^a,b,c,d,e,f  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f GLASGOW ROYAL INFIRMARY   (United Kingdom)

^g UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Clinical trial; Functional genomics; Genome sequencing; Molecular heterogeneity; Molecular taxonomy; Pancreatic cancer

Indexed keywords

CISPLATIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PLATINUM DERIVATIVE; TRASTUZUMAB;

ADVANCED CANCER; ARID1A GENE; ARID2 GENE; ARTICLE; ATM GENE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CDKN2A GENE; COPY NUMBER VARIATION; EPC1 GENE; FUNCTIONAL GENOMICS; GENE INACTIVATION; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; MAP2K4 GENE; METASTASIS POTENTIAL; MLL3 GENE; MOLECULAR PATHOLOGY; NALCN GENE; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PATIENT CARE; PLXNA1 GENE; ROBO1 GENE; ROBO2 GENE; SEMA3A GENE; SF3B1 GENE; SLC16A4 GENE; SLIT2 GENE; SMAD4 GENE; TGFBR2 GENE; TP53 GENE; TUMOR GENE; TUMOR SUPPRESSOR GENE; ZIM2 GENE; CARCINOGENESIS; GENETICS; GENOMICS; PANCREAS TUMOR; PROCEDURES;

CARCINOGENESIS; GENOMICS; HUMANS; PANCREATIC NEOPLASMS;

EID: 84881474788     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-013-0610-6     Document Type: Article

References (23)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: A Cancer J Clin. 2012;62(1):10-29. doi: 10.3322/caac.20138.
2. Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JH, Bakkevold KE, et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg. 2008;143(1):75-83. doi: 10.1001/archsurg.2007.17 (Discussion).
3. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073-81. doi: 10.1001/jama.2010.1275.
4. Hruban RH, Maitra A, Goggins M. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol. 2008;1(4):306-16.
5. Samuel N, Hudson TJ. The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;. doi: 10.1038/nrgastro.2011.215.
6. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabe RR, et al. International network of cancer genome projects. Nature. 2010;464(7291):993-8. doi: 10.1038/nature08987.
7. Song S, Nones K, Miller D, Harliwong I, Kassahn KS, Pinese M, et al. qpure: a tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. PLoS ONE. 2012;7(9):e45835. doi: 10.1371/journal.pone. 0045835.
8. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801-6. doi: 10.1126/science.1164368.
9. Dees ND, Zhang Q, Kandoth C, Wendl MC, Schierding W, Koboldt DC, et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res. 2012;22(8):1589-98. doi: 10.1101/gr.134635.111.
10. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399-405. doi: 10.1038/nature11547.
11. Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012;2(1):41-6. doi: 10.1158/2159-8290.cd-11-0194.
12. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41. doi: 10.1186/gb-2011-12-4-r41.
13. Mann KM, Ward JM, Yew CC, Kovochich A, Dawson DW, Black MA, et al. Sleeping beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci USA. 2012;109(16):5934-41. doi: 10.1073/pnas.1202490109.
14. Perez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature. 2012;486(7402):266-70. doi: 10.1038/nature11114.
15. Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci USA. 2011;108(30):12372-7. doi: 10.1073/pnas.1109363108.
16. Sun W, Wright FA, Tang Z, Nordgard SH, Van Loo P, Yu T, et al. Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res. 2009;37(16):5365-77. doi: 10.1093/nar/gkp493.
17. Mehlen P, Delloye-Bourgeois C, Chedotal A. Novel roles for slits and netrins: axon guidance cues as anticancer targets? Nat Rev Cancer. 2011;11(3):188-97. doi: 10.1038/nrc3005.
18. Pajic M, Scarlett CJ, Chang DK, Sutherland RL, Biankin AV. Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Hum Genet. 2011;130(1):93-101. doi: 10.1007/s00439-011-0990-0.
19. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97. doi: 10.1016/s0140-6736(10)61121-x.
20. Blackwell K, Miles D, Gianni L. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J Clin Oncol. 2012;30(18 Suppl):810.
21. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-25. doi: 10.1056/NEJMoa1011923.
22. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960-6. doi: 10.1200/JCO.2006.07.9525.
23. Eifert C, Powers RS. From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. Nat Rev Cancer. 2012;12(8):572-8. doi: 10.1038/nrc3299.